Catalyst Pharmaceuticals Announces Support of Rare Disease Day 2021
February 22 2021 - 8:03AM
Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a
commercial-stage biopharmaceutical company focused on developing
and commercializing innovative therapies for people with rare
debilitating, chronic neuromuscular and neurological diseases,
today announced its support for Rare Disease Day 2021.
Rare Disease Day, observed on February 28th this
year, involves activities worldwide to raise awareness of rare
diseases and their impact on patients’ lives among the general
public and decision-makers in industry and government. Efforts
taken on this day (and throughout the year) are hoped to increase
funds, research, resources, and treatments for the rare disease
community. Only 5% of the over 7,000 identified rare diseases have
an FDA approved treatment.
As a public demonstration of support, members of
Catalyst’s team will be joining the National Organization for
Rare Disorders, also known as NORD, in their “Show Your Stripes”
campaign by wearing zebra stripes to raise awareness for rare
disease. In addition, Catalyst will be launching its own “Rare
Reason” social initiative to showcase the reason, the dedication,
the drive, behind individuals involved in the rare disease
community. Employees, key opinion leaders, and individual patients
are invited to share their reason for working in and being involved
with, the rare disease community using #RareReason on social media.
Keep an eye on Catalyst’s social channels @CatalystForRare to see
#RareReason videos.
Dedicated to raising awareness of rare disease
and its challenges; Catalyst is sponsoring and will participate in
a February 26th Facebook Live event covering topics spanning from
adult-onset rare disease, misdiagnosis, and living with chronic
illness and, hosted by The Mighty, the world’s leading online
patient community. The panel will be moderated by Mike Porath,
founder and CEO of The Mighty, with discussion from, Chip, a
Lambert-Eaton Myasthenic Syndrome (LEMS) patient advocate, and Dr.
Ericka Greene, Neurologist, Houston Methodist.
"Rare disease day is a great opportunity to
drive awareness around the rare diseases that 300 million people
live with," said Mike Porath, founder and CEO of The Mighty. "It's
also an opportunity to drive collaboration among the patients,
caregivers, doctors, drug makers and more who are working to
improve the lives of those living with rare diseases. We're proud
to help bring these people and organizations together."
Details of the Facebook Live
event |
Location: |
https://bit.ly/CatalystFBLive2021 |
Date: |
Friday, February 26th |
Time: |
4:00 pm – 4:45 pm ET |
Moderator: |
Mike Porath, Founder and CEO of The Mighty |
Panelist: |
Chip, a LEMS patient ambassador |
|
Dr. Ericka Greene, Neurologist, Houston Methodist
|
Subject: |
Late-onset diagnosis of rare disease, misdiagnosis, and living
with a chronic illness from a patient and HCP perspective |
“With over 300 million members, we are proud to
support the effort to build unity within the rare and ultra-rare
disease community," said Patrick J. McEnany, Chairman and CEO of
Catalyst. “This year we are honored to provide our employees,
patients, advocates, and family members a platform to amplify their
voice and showcase their dedication and passion in advocating for
the rare and ultra-rare disease community. Through this initiative
we will continue to educate and raise awareness on the prevalence
and challenges of those living with a rare disease.”
For information about Rare Disease Day
activities,
visit https://rarediseases.org/rare-disease-day/.
About Catalyst
Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage
biopharmaceutical company focused on developing and commercializing
innovative therapies for people with rare debilitating, chronic
neuromuscular and neurological diseases, including Lambert-Eaton
myasthenic syndrome (LEMS), anti-MuSK antibody positive myasthenia
gravis (MuSK-MG) and other neurological and neuromuscular
disorders. Catalyst's New Drug Application for Firdapse®
(amifampridine) 10 mg tablets for the treatment of adults with LEMS
was approved in 2018 by the U.S. Food & Drug
Administration ("FDA"), and Firdapse is now commercially
available in the United States. Further, Canada’s national
healthcare regulatory agency, Health Canada, recently approved the
use of Firdapse® (amifampridine) for the treatment of patients in
Canada with LEMS.
Firdapse is currently being evaluated in
clinical trials for the treatment of MuSK-MG and has received
Orphan Drug Designation from the FDA for myasthenia
gravis.
About The Mighty
The Mighty is the world’s leading health
community, revolutionizing the way people think and talk about
health. With more than 3 million members and billions of views on
the health stories their members share, The Mighty provides its
members with connection and support and provides its partners with
insights and marketing opportunities across thousands of health
conditions, including many rare diseases.
Forward-Looking Statements
This press release contains forward-looking
statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results
in future periods to differ materially from forecasted results. A
number of factors, including those factors described in Catalyst's
Annual Report on Form 10-K for fiscal year 2019 and its other
filings with the U.S. Securities and Exchange Commission (SEC),
could adversely affect Catalyst. Copies of Catalyst's filings with
the SEC are available from the SEC, may be found on Catalyst's
website, or may be obtained upon request from Catalyst. Catalyst
does not undertake any obligation to update the information
contained herein, which speaks only as of this date.
Investor Contact |
Company Contact |
Brian Korb |
Patrick J. McEnany |
Solebury Trout |
Catalyst Pharmaceuticals |
(646) 378-2923 |
Chief Executive Officer |
bkorb@troutgroup.com |
(305) 420-3200 |
|
pmcenany@catalystpharma.com |
|
|
Media Contact |
|
David Schull |
|
Russo Partners |
|
(212) 845-4271 |
|
david.schull@russopartnersllc.com |
|
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Pharmaceuticals (NASDAQ:CPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024